ISPOR

ISPOR
Name	ISPOR
Formation	1995
Type	Professional association
Headquarters	United States
Region served	Global
Membership	Health economics, outcomes research professionals
Leader title	President

ISPOR is an international professional association devoted to health economics and outcomes research, pharmacoeconomics, and health policy analysis. Founded in the mid-1990s, the association has become a central forum linking practitioners, academics, industry, regulators, and payers across multiple jurisdictions. It organizes conferences, issues methodological guidance, and publishes research that informs regulatory decisions, reimbursement, and clinical guideline development.

History

ISPOR was established in 1995 amid growing interest in pharmacoeconomics following developments such as the launch of the World Health Organization's expanded role in health technology assessment and the broader diffusion of cost-effectiveness analysis exemplified by early work in United Kingdom health policy debates. Founders drew on precedents from organizations like the International Society for Pharmacoeconomics and collaborations with stakeholders in United States, Canada, Australia, and Sweden. During the 2000s the society expanded alongside events including the implementation of the Affordable Care Act debates in the United States and the maturation of health technology assessment agencies such as the National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health. Growth paralleled methodological advances represented by landmark works from scholars associated with Harvard University, Johns Hopkins University, University of Oxford, Imperial College London, and McMaster University. The organization’s trajectory intersected with policy episodes in the European Union, the establishment of formal HTA networks like the European Network for Health Technology Assessment, and increased industry engagement from multinational firms headquartered in Switzerland, Germany, France, Japan, and United Kingdom.

Organization and Governance

ISPOR’s governance model mirrors structures used by associations such as the American Medical Association, the International Society for Clinical Biostatistics, and the World Psychiatric Association, featuring a board of directors, executive committees, and specialty working groups. Leadership roles have engaged professionals affiliated with institutions including Centers for Disease Control and Prevention, Food and Drug Administration, European Medicines Agency, GlaxoSmithKline, Pfizer, Roche, Novartis, and academic centers such as Stanford University and University College London. The governance framework incorporates committees on ethics, methodology, and conflict of interest similar to processes used by the Institute of Medicine and the International Committee of Medical Journal Editors. Regional representation echoes models from the Pan American Health Organization and the Asia-Pacific Economic Cooperation health working groups.

Activities and Conferences

ISPOR hosts major conferences that attract delegates comparable to those at meetings like the American Public Health Association, the European Society for Medical Oncology, and the European Public Health Association. Annual scientific meetings and regional congresses convene presenters from World Bank health projects, national health ministries such as the Ministry of Health (Brazil), regulatory authorities like the Therapeutic Goods Administration (Australia), and payer organizations including Centers for Medicare & Medicaid Services. The program frequently features sessions on methods developed at centers such as RAND Corporation, Cleveland Clinic, Mayo Clinic, Karolinska Institutet, and The George Institute for Global Health. Workshops often include contributors from philanthropic organizations like the Bill & Melinda Gates Foundation and international initiatives such as the Global Fund.

Publications and Guidelines

The society issues methodological task force reports and good-practice guidelines that are cited alongside publications from journals such as The Lancet, The BMJ, Health Affairs, Value in Health, and PharmacoEconomics. Its guidance addresses cost-effectiveness analysis, budget impact modeling, real-world evidence, and patient-reported outcomes, intersecting with standards advanced by groups including the International Society for Quality of Life Research, CONSORT Group, STROBE, and the Grading of Recommendations Assessment, Development and Evaluation working group. Contributors hail from research centers like Yale University, Columbia University, Duke University, and University of Toronto. The society’s methods inform submissions to agencies such as the National Institute for Health and Care Excellence and influence the work of reimbursement bodies like the Institute for Clinical and Economic Review.

Membership and Chapters

ISPOR’s membership model includes individual and corporate members from academia, industry, consultancy, and government agencies, paralleling structures used by the American Statistical Association and the Royal Society of Medicine. Regional chapters and affiliates operate in geographies including Latin America, Africa, Asia, and Europe, with national chapters interacting with professional bodies such as the Brazilian Association of Health Economics, the Japanese Society of Health Economics and Policy, and the European Federation of Pharmaceutical Industries and Associations. Members often maintain ties to universities and hospitals including King’s College London, University of Melbourne, Peking University, Seoul National University Hospital, and research institutes like the Institute for Health Metrics and Evaluation.

Impact and Criticism

ISPOR’s influence extends to policy debates involving agencies like the European Medicines Agency and payer organizations such as Medicare; its methods have shaped formularies and reimbursement decisions worldwide. The society’s role has been lauded by stakeholders including academics at Brown University and practitioners at Eli Lilly and Company for advancing methodological rigor. Criticisms echo concerns raised in discussions around pharmaceutical industry engagement and transparency, similar to debates involving the National Academies of Sciences and ethical reviews by the Hastings Center, with commentators from outlets like The New York Times and The Economist questioning conflicts of interest and industry funding. Debates have addressed the balance between methodological standardization and adaptability to local contexts, reflecting tensions seen in deliberations at the World Health Assembly and regional forums such as the African Union health policy meetings.

Category:Health economics